![]() ![]() While novel treatment strategies are emerging for MDD, objective biomarkers of disease progression and treatment response are lacking. ![]() Newer therapies, including psilocybin and ketamine or intranasal esketamine, are among several compounds being evaluated for their ability to treat MDD, particularly in treatment-resistant depression 3, 4, 5. The standard treatments for depression include combinations of psychotherapy and pharmacotherapy. In 2018, the economic burden of adults with MDD was $326.2 billion USD 2. In addition to the immense personal and social impact of this disease, untreated or refractory MDD represents a major societal challenge. The lifetime incidence of Major Depressive Disorder (MDD) is estimated to be 12% in men and up to 20% in women 1. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |